Delamanid for MDR-TB:
Current Development Progress and Ongoing Access Plans
Charles D. Wells, MD
Background: The Otsuka Philosophy

Different Approach from Other Life Science Companies

• Screening anti-TB compounds for >30 years
• However, “global health” a new area for Otsuka
• Specialize in long-term effective treatments requiring strong safety profile
• Strong commitment to avoid emergence of resistance

Long-term vision: Development of entire disease-management portfolio

• More than 1 new compound, we have an active R&D portfolio of several products aimed at changing the paradigm of MDR-TB management
  – Only possible by working on issues related to diagnosis, treatment monitoring and treatment regimens
Our Priority: Roll-Out Delamanid *Safely* and *Responsibly*

- Early global health products benefited from wide-scale use prior to introduction in resource-limited settings (e.g. ARVs for HIV)
  - Comfortable post-approval safety database with 10-20x the number of patients in standard phase 2 or phase 3 MDR-TB clinical trial

- Delamanid has received *conditional* approval by stringent regulatory authorities
  - In Japan we are required to track and trace every patient for 10 years

- A risk management plan is implemented for all patients including:
  - Distribution (criteria for patients, physicians, hospitals)
  - Education and training (patients, physicians, hospitals)
  - Data collection (registry)
  - Delamanid drug susceptibility testing
  - Safety reporting (pharmacovigilance)
Update on Development Activities

Phase III Trial

• 511 patients enrolled
  – Randomized 2:1 ratio (DLM:PLC)
  – First use of DLM & moxifloxacin
  – Nested cohort of HIV+ positive patients on ARV treatment
     No DDI issues with ARVs or second-line drugs for DLM

• No additional safety concerns to date

Pediatric Development Program

• Delamanid only pediatric formulation of 2nd-line anti-TB drug with ongoing studies and results being published
  – How can we work with the community to stimulate generation of more PK data and encourage pediatric formulations for other 2nd-line drugs?
The Way Forward

• Otsuka believes the way forward for successful introduction of DLM requires:
  – Long-term strategic planning
  – Careful introduction in quality TB management programs
  – Country level support for implementation
  – Prevention of additional drug resistance
  – Strengthened pharmacovigilance systems

• Sometimes perceived as in conflict with pressure to make delamanid available as soon as possible, to as many people as possible, worldwide

• We have heard the urgent needs of TB community and are responding by introducing a comprehensive, multi-stakeholder initiative addressing delamanid access for MDR-TB
“Otsuka’s FighTBack Initiative”
The Goal

“20 by 2020”

By 2020, at least 20% of diagnosed and treated MDR-TB patients should have delamanid as part of their treatment regimen through high-quality programs.
Core Components – 4 Pillars

- Innovative Research and Development
- Responsible Access to Patients
- Optimized Patient Management
- Collaborative Capacity Building